日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Lymphoma-on-chip model reveals that lymph node stromal cells promote diffuse large B-cell lymphoma survival and migration

芯片淋巴瘤模型揭示淋巴结基质细胞促进弥漫性大B细胞淋巴瘤的存活和迁移

Mohammad Jouybar ,Aleksandra M Mikula ,Nanouk Zuidmeer ,Tanja Konijn ,A Vera de Jonge ,Henk P Roest ,Tuna Mutis ,Luc J W van der Laan ,Reina E Mebius ,Jaap M J den Toonder ,Charlotte M de Winde

Surface downmodulation of TIM3 safeguards healthy cells but not acute myeloid leukemia from CAR T-cell therapy

TIM3表面表达下调可保护健康细胞免受CAR-T细胞疗法的损伤,但不能保护急性髓系白血病细胞免受损伤。

Jort J van der Schans ,Paresh Vishwasrao ,Renée Poels ,Morgan Antti ,Ziyu Wang ,Marjolein Quik ,Jennemiek van Arkel ,Tom Reuvekamp ,Niels W C J van de Donk ,Maria Themeli ,Gert J Ossenkoppele ,Arjan A van de Loosdrecht ,Rebecca Richards ,Tuna Mutis

Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS

HGBL-MYC/BCL2 患者与 DLBCL NOS 患者外周 T 细胞和 NK 细胞谱存在显著差异。

A Vera de Jonge ,Carolien Duetz ,Wassilis S C Bruins ,Charlotte L B M Korst ,Rosa Rentenaar ,Meliha Cosovic ,Merve Eken ,Inoka Twickler ,Marcel Nijland ,Marjolein W M van der Poel ,Koen de Heer ,Clara P W Klerk ,Leonie Strobbe ,Margriet Oosterveld ,Rinske Boersma ,Harry R Koene ,Margaretha G M Roemer ,Erik van Werkhoven ,Martine E D Chamuleau ,Tuna Mutis

A convenient viral transduction based method for advanced multi-engineering of primary human (CAR) T-cells

一种便捷的基于病毒转导的用于原代人T细胞(CAR)高级多重工程改造的方法

Jort J van der Schans ,Afroditi Katsarou ,George Kladis ,Citlali Bar ,Max Medina Ramirez ,Maria Themeli ,Tuna Mutis

Delineating MYC-Mediated Escape Mechanisms from Conventional and T Cell-Redirecting Therapeutic Antibodies

阐明 MYC 介导的常规和 T 细胞重定向治疗性抗体的逃逸机制

Anna Vera de Jonge, Tamás Csikós, Merve Eken, Elianne P Bulthuis, Pino J Poddighe, Margaretha G M Roemer, Martine E D Chamuleau, Tuna Mutis

Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138

针对 CD38 和 CD138 的双重分裂信号嵌合抗原受体 T 细胞对多发性骨髓瘤的特异性靶向治疗

Jort J van der Schans, Ziyu Wang, Jennemiek van Arkel, Thijs van Schaik, Afroditi Katsarou, Ruud Ruiter, Thomas Baardemans, Huipin Yuan, Joost de Bruijn, Sonja Zweegman, Niels W C J van de Donk, Richard W J Groen, Maria Themeli, Tuna Mutis

Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity

HexaBody-CD38 的临床前抗肿瘤活性,这是一种具有优异补体依赖性细胞毒活性的下一代 CD38 抗体

Ida H Hiemstra, Kim C M Santegoets, Maarten L Janmaat, Bart E C G De Goeij, Wessel Ten Hagen, Sanne van Dooremalen, Peter Boross, Jeroen van den Brakel, Sieto Bosgra, Grietje Andringa, Berris van Kessel-Welmers, Dennis Verzijl, Richard G Hibbert, Kristine A Frerichs, Tuna Mutis, Niels W C J van de D

Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence

将CAR与嵌合共刺激受体结合,可增强T细胞对低抗原密度的敏感性并促进其持久性。

Afroditi Katsarou,Maria Sjöstrand,Jyoti Naik,Jorge Mansilla-Soto,Dionysia Kefala,Georgios Kladis,Alexandros Nianias,Ruud Ruiter,Renée Poels,Irene Sarkar,Yash R Patankar,Elena Merino,Rogier M Reijmers,Kristine A Frerichs,Huipin Yuan,Joost de Bruijn,Dina Stroopinsky,David Avigan,Niels W C J van de Donk,Sonja Zweegman,Tuna Mutis,Michel Sadelain,Richard W J Groen,Maria Themeli

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies

针对多发性骨髓瘤和其他 CD38 阳性恶性肿瘤联合使用 PD-1/PD-L1 轴和 CD38 抗体的临床前原理

Christie P M Verkleij, Amy Jhatakia, Marloes E C Broekmans, Kristine A Frerichs, Sonja Zweegman, Tuna Mutis, Natalie A Bezman, Niels W C J van de Donk

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

针对血液系统恶性肿瘤及其他疾病的 CD38 单克隆抗体

Niels W C J van de Donk, Maarten L Janmaat, Tuna Mutis, Jeroen J Lammerts van Bueren, Tahamtan Ahmadi, A Kate Sasser, Henk M Lokhorst, Paul W H I Parren